Hepatitis C Therapy: Lessons of the Last Two Decades Sudeep TanwarPaul M. TremblingGeoffrey M. Dusheiko Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 15 August 2012 Pages: 119 - 127
Impact of Ethnicity and Race on Treatment Response: Past, Present and Future Maribel Rodríguez-TorresDeana Hallman Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 15 July 2012 Pages: 128 - 135
IL28B: Current and Future Use S. G. Chen Yi MeiP. V. DesmondA. J. Thompson Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 28 July 2012 Pages: 136 - 145
Non-interferon Therapies for Hepatitis C Fernando E. MembrenoEric J. Lawitz Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 25 July 2012 Pages: 146 - 152
Cyclophilin Inhibitors Robert FlisiakAnna Parfieniuk-Kowerda Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 05 July 2012 Pages: 153 - 159
Telaprevir and Boceprevir: The Future Is Now Beatriz Calle SerranoMichael P. Manns Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 01 September 2012 Pages: 160 - 171
Second Generation Protease Inhibitors and Nucleotide Inhibitors Syed-Mohammad JafriStuart C. Gordon Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 20 July 2012 Pages: 172 - 180
NS5A Inhibitors Christopher O’BrienNicholas Agresti Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 10 August 2012 Pages: 181 - 187
Resistance to Direct-Acting Antivirals Jean-Michel Pawlotsky Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors) 02 August 2012 Pages: 188 - 194